amoxycillin/clavulanate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   42 Trials   42 Trials   2742 News 


«12...34353637383940414243444546»
  • ||||||||||  Journal:  Bacterial keratitis due to Moraxella nonliquefaciens. (Pubmed Central) -  Jun 8, 2021   
    Keratitis caused by M. nonliquefaciens is rare and must be suspected in elderly patients with local predisposing factors, such as corneal damage or previous eye surgery. Early antibiogram-guided treatment and close monitoring are important to avoid complications and poor compliance.
  • ||||||||||  ampicillin / Generic mfg.
    Clinical, Journal:  Clinical significance of Proteus mirabilis bacteriuria in dogs, risk factors and antimicrobial susceptibility. (Pubmed Central) -  Jun 8, 2021   
    To conclude, P. mirabilis bacteriuria was associated with upper and lower urinary tract infections in this study and was found more frequently in complicated bacterial cystitis. Multidrug-resistant isolates and increased P. mirabilis antimicrobial resistance have been identified over the last 10 years, but most isolates remain susceptible to first-line antimicrobials such as amoxicillin and trimethoprim-sulfamethoxazole.
  • ||||||||||  amoxycillin/clavulanate / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date, HEOR, Cost effectiveness:  RAIN: Reduction of Intravenous Antibiotics In Neonates (clinicaltrials.gov) -  May 27, 2021   
    P4,  N=510, Active, not recruiting, 
    Levels of contamination were on average 3.0E+03 CFU/g, 4.4E+02 CFU/g and 4.2E+04 CFU/g in commercial broiler, free range and backyard chicken, respectively. Recruiting --> Active, not recruiting | Trial completion date: Mar 2021 --> Jul 2021 | Trial primary completion date: Mar 2021 --> Jun 2021
  • ||||||||||  [VIRTUAL] National trends in outpatient antibiotic use in the United States (US): 2011 to 2018 () -  May 20, 2021 - Abstract #ECCMID2021ECCMID_3591;    
    Outpatient antibiotic prescribing has decreased in the national VA system, with an overall annual reduction of 3.9%, and a reduction in ciprofloxacin use of 12.6% per year.  This may be related to VA antibiotic stewardship programs. Despite reduced utilization of some antibiotics, use of the three most commonly prescribed outpatient antibiotics remained stable . Our study identified target areas for outpatient antibiotic stewardship activities to reduce unnecessary antibiotic use.
  • ||||||||||  ceftriaxone / Generic mfg.
    [VIRTUAL] Improved antibiotic use in 342 nursing homes: data from a national network 2018-2019 () -  May 20, 2021 - Abstract #ECCMID2021ECCMID_3589;    
    It may also result from national decisions regarding withdrawing of reimbursement for flumequine in 2018 and for norfloxacin and lomefloxacin in 2019 . This study highlights the feasibility of a retrospective surveillance of dispensed antibiotics and its usefulness to promote benchmarking, raise prescribers awareness and monitor the effect of national policies.
  • ||||||||||  piperacillin sodium/tazobactam sodium / Generic mfg., metronidazole oral / Generic mfg., amoxycillin/clavulanate / Generic mfg.
    Enrollment open, Head-to-Head, Surgery:  PIPA: Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis. (clinicaltrials.gov) -  May 10, 2021   
    P=N/A,  N=2631, Recruiting, 
    This case also highlights the need to adjust the steroid regimen to reduce the potentially harmful effects on various organ systems. Not yet recruiting --> Recruiting
  • ||||||||||  [VIRTUAL] Antibiotic Resistant Bacteria Isolated in Spring Mineromedicinal Water from Ecuador (Poster Hall) -  May 9, 2021 - Abstract #WMF2021WMF_4138;    
    Not yet recruiting --> Recruiting The results obtained indicate the need to carry out epidemiological surveillance studies in the mineral-medicinal water spas of Ecuador, since they are used by a large number of people who come to these environments to seek relief from their illnesses, many of which may have their altered immune defenses, and could put their health at risk when they come into contact with bacterial strains resistant and multi-resistant to a wide variety of antibiotics
  • ||||||||||  ciprofloxacin oral / Generic mfg., piperacillin sodium/tazobactam sodium / Generic mfg., amoxycillin/clavulanate / Generic mfg.
    [VIRTUAL] Modelling Antibiotic-induced Dysbiosis (Poster Hall) -  May 9, 2021 - Abstract #WMF2021WMF_3362;    
    Also, functional pathways between models during pathogen challenge revealed differences in the metabolic potential of the respective pan genomes. Instillation of MAs created long-term dysbiosis, whilst the dysbiosis induced by single NSA or BSA was transient.
  • ||||||||||  ceftriaxone / Generic mfg., ampicillin / Generic mfg., cefuroxime / Generic mfg.
    [VIRTUAL] First Detection of Resistance Mechanisms to Third Generation Cephalosporins in Escherichia coli Fecal Samples from Dogs in Uruguay (Poster Hall) -  May 9, 2021 - Abstract #WMF2021WMF_2812;    
    The identification of different transferable resistance mechanisms to highest critically important antibiotics triggers an alarm about this potential reservoir for dissemination of resistant strains to humans. Colistin and fosfomycin constitute one of the last resorts for the treatment of human infections by multiresistant microorganisms, and the presence of mcr-1 and fosA3 in these isolates is worrisome.
  • ||||||||||  ceftriaxone / Generic mfg., cefuroxime / Generic mfg.
    [VIRTUAL] Gold Nanoparticles Conjugated with Antibiotics for the Treatment of Urinary Infections (Poster Hall) -  May 9, 2021 - Abstract #WMF2021WMF_2248;    
    Preliminary results, showed interesting potential of Au-Nps in the treatment of biofilms. Future work will be centered in the study of the effect of this Nps in intracellular bacterial communities in bladder cell cultures and also to direct the Nps to uroepithelial cells.
  • ||||||||||  ceftriaxone / Generic mfg., ampicillin / Generic mfg.
    [VIRTUAL] Evaluation of Antimicrobial Susceptibility of Yersinia Spp Using Broth Microdilution (Poster Hall) -  May 9, 2021 - Abstract #WMF2021WMF_1733;    
    Our results indicate that from 2014-2019 there was no marked decreased susceptibility to agents commonly used for therapy among Yersinia spp in the U.S. The high ampicillin, amoxicillin/clavulanic acid and cefoxitin MICs are consistent with the fact that Yersinia spp often produce beta-lactamase. Antimicrobial susceptibility should be monitored periodically to identify important changes in susceptibility in this pathogen as early as possible.
  • ||||||||||  colistin sulphate / Generic mfg.
    [VIRTUAL] Detection of Beta-lactam and Colistin Resistant Gram-negative Bacteria in Ready-to-eat Vegetables (Poster Hall) -  May 9, 2021 - Abstract #WMF2021WMF_605;    
    Under COL selection we identified one Yersinia enterocolitica (from carrot), we also identified 37,8% Pseudomonas spp.;12,5% Rahnella spp.; 12,5% Herbaspirillum spp.; and 25,0% Serratia spp., all resistant to COL, but susceptible to β-lactam antibiotics; only one Pseudomonas spp. was resistant to all antibiotics except IMP.Overall, it was identified a Y. enterocolitica in RTE carrot, which causes human gastroenteritis, and diverse opportunistic pathogens, such as K. oxytoca, that showed resistance to clinically important antibiotics Our results highlight the importance of microbiological evaluation of pre-washed RTE salads.
  • ||||||||||  ampicillin / Generic mfg., meropenem / Generic mfg.
    [VIRTUAL] Prevalence and Seasonal Disparity of Meropenem Resistant E. coli in Sewage Water in Islamabad, Pakistan (Poster Hall) -  May 9, 2021 - Abstract #WMF2021WMF_452;    
    All environmental meropenem resistant E. coli were MDR and mostly belonged to commensals phylogenetics group (clad I/II) which indirectly represents the community carriage and potential hazard for public health. Co-occurrence of carbapenemases with ESBLs and PMQRs in E. coli in environment calls for extensive surveillance and prompt action to control clinically important resistant bacteria in environment before they become part of ecosystem.
  • ||||||||||  Orapenem (tebipenem pivoxil) / Meiji Seika, GSK
    Trial completion:  Effect of Tebipenem on Normal Human Intestinal Microbiota (clinicaltrials.gov) -  May 3, 2021   
    P1,  N=30, Completed, 
    TBP provides good coverage against less common penicillin susceptible Gram positive UTI and common URTI bacterial pathogens. Active, not recruiting --> Completed
  • ||||||||||  amoxycillin/clavulanate / Generic mfg., amoxicillin / Generic mfg.
    Trial completion date, Trial primary completion date:  An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following Dental Procedures (clinicaltrials.gov) -  Apr 30, 2021   
    P4,  N=150, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Feb 2019 --> Dec 2021 | Trial primary completion date: Dec 2018 --> Dec 2021
  • ||||||||||  linezolid oral / Generic mfg.
    Enrollment change, Trial termination:  PRESTO:Osteo: Patients Response to Early Switch To Oral:Osteomyelitis Study (clinicaltrials.gov) -  Apr 6, 2021   
    P1,  N=11, Terminated, 
    The high prevalence of MDR MRSA in frozen chicken meat samples in this study emphasizes the need for better sanitary education of food handlers in hygienic practices focusing on their potential role as reservoirs and spreaders of MRSA. N=456 --> 11 | Recruiting --> Terminated; Not enough patient enrollment and lack of staffing
  • ||||||||||  amoxycillin/clavulanate / Generic mfg.
    Enrollment open:  OURBIOTIC: Mechanisms of Probiotics and Antibiotic-Associated Diarrhea (clinicaltrials.gov) -  Feb 17, 2021   
    P1,  N=124, Recruiting, 
    The data suggest that cats with azCKD have altered pharmacokinetics of amoxicillin, which may contribute to an increased incidence of multiple side effects. Not yet recruiting --> Recruiting
  • ||||||||||  amoxycillin/clavulanate / Generic mfg.
    Trial completion date, Trial primary completion date:  EPAAC: Effects of Phenoximethylpenicillin, Amoxicillin and Amoxicillin-clavulanic Acid on the Gut Microbiota (clinicaltrials.gov) -  Nov 18, 2020   
    P4,  N=120, Recruiting, 
    Recruiting --> Completed | Trial completion date: Jan 2020 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Jul 2020 Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022